Pharmaceutical Executive

Pharmaceutical Executive: January 2023
Volume: 43
Issue: 01

Pharmaceutical Executive-12-01-2022
Volume: 42
Issue: 12

Pharmaceutical Executive-11-01-2022
Volume: 42
Issue: 11

Pharmaceutical Executive-10-01-2022 APEX Awards Program

Pharmaceutical Executive-10-01-2022
Volume: 42
Issue: 10

Pharmaceutical Executive-09-01-2022
Volume: 42
Issue: 9

Pharmaceutical Executive-08-01-2022
Volume: 42
Issue: 8

Pharmaceutical Executive-07-01-2022
Volume: 42
Issue: 7

Pharmaceutical Executive-06-01-2022
Volume: 42
Issue: 6

Pharmaceutical Executive-05-01-2022
Volume: 42
Issue: 5

Pharmaceutical Executive-04-01-2022
Volume: 42
Issue: 4

Pharmaceutical Executive-03-01-2022
Volume: 42
Issue: 3

Pharmaceutical Executive-02-01-2022
Volume: 42
Issue: 2

Pharmaceutical Executive-01-01-2022
Volume: 42
Issue: 1

Pharmaceutical Executive-12-01-2021
Volume: 41
Issue: 12

Pharmaceutical Executive-11-01-2021
Volume: 41
Issue: 11

Pharmaceutical Executive-10-01-2021
Volume: 41
Issue: 10

Pharmaceutical Executive-09-01-2021
Volume: 41
Issue: 9

Pharmaceutical Executive-08-01-2021
Volume: 41
Issue: 8

Pharmaceutical Executive-07-01-2021
Volume: 41
Issue: 7

Pharmaceutical Executive-06-01-2021
Volume: 41
Issue: 6

Pharmaceutical Executive-05-01-2021
Volume: 41
Issue: 5

Pharmaceutical Executive-04-01-2021
Volume: 41
Issue: 4

Pharmaceutical Executive-03-01-2021
Volume: 41
Issue: 3

Pharmaceutical Executive-02-01-2021
Volume: 41
Issue: 2

Pharmaceutical Executive-01-01-2021
Volume: 41
Issue: 1

Pharmaceutical Executive-12-01-2020
Volume: 40
Issue: 12

Pharmaceutical Executive-11-01-2020
Volume: 40
Issue: 11

Pharmaceutical Executive-10-01-2020
Volume: 40
Issue: 10

Pharmaceutical Executive-09-01-2020
Volume: 40
Issue: 9
Advertisement
Advertisement
Trending on PharmExec
1
Brent Saunders: Eyeing New Horizons
2
TrumpRX Has a Blind Spot and It Can Redefine Patient Access
3
Lilly’s Retatrutide Displays Positive Topline Results in Successful Phase III Trial
4
FDA Approves Amgen's Uplizna for Generalized Myasthenia Gravis With Positive AChR or MuSK Antibodies
5

